Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Merck’s Covid Pill Narrowly Gets Backing From FDA Advisers (2)

Dec. 1, 2021, 12:42 AM

Merck & Co.’s Covid-19 pill narrowly gained a key recommendation from advisers to U.S. regulators, after a lengthy debate about the safety of the potential game-changing treatment.

The Food and Drug Administration’s advisory committee voted 13-10 to back Merck’s antiviral drug molnupiravir, saying that while there were safety concerns about the pill, its potential benefits outweigh the risks.

The pill is intended to treat mild-to-moderate Covid-19 in adults at risk of developing severe illness. Merck developed the treatment with partner Ridgeback Biotherapeutics LP.

Merck’s shares rose 1.9% in late trading as the vote increased the likelihood that the ...